Pipeline

뒷 페이지 앞 페이지

Pipeline

New Drug

Disease Area

Code

Indication

Research

Preclinical

PhaseⅠ

PhaseⅡ

PhaseⅢ

NDA

Remark

Metabolic
Diseases

  • Diabetes

  • Diabetes

  • Diabetes

  • Gout

  • NASH

  • NASH

  • Obesity

  • Obesity

  • Obesity

Oncology

  • Oncology

  • Oncology

  • Oncology

  • Oncology

  • Oncology

  • Solid Tumor

Immunology

  • LR19019

  • LR20016

  • LR19055

  • LR19025

  • LR19024

  • LR21004

  • Atopic Dermatitis

  • Atopic Dermatitis

  • Autoimmune Disease

  • Degenerative Disease

  • Degenerative Disease

  • Osteoarthritis

  • combination drug (Korea)

  • combination drug (Thailand)

  • US

  • In partnership with

    (China)

  • US

  • In partnership with

    (US)

  • In partnership with

    (US)

  • In partnership with

    (US)

  • In partnership with

    (Korea)

  • In partnership with

    (Korea)

  • In partnership with

    (Korea)

Vaccine

Vaccine

  • LR19113

  • LR19122

  • Polio

  • 6-in-1
    (Diphtheriae,
    Tetanus,
    Pertussis,
    Hepatitis B,
    Meningitis,
    Polio)

  • Funded by BMGF*
    Received export license from MFDS**

  • Funded by BMGF*

Medical Device

Dermal Filers

  • LR19093

  • LR20024

  • LR20008

  • Facial etc.

  • Facial etc.

  • Next
    generation
    filer

Botulinum toxin

  • LR20023

  • Moderate to
    severe
    glabellar lines

  • Medical Device
    (China)

  • Medical Device
    (Europe)

  • In partnership with

    (Korea)

Disease Area

Phases

LR19052

Diabetes

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19051

Diabetes

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19123

Diabetes

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Gout

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

NASH

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19018

NASH

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Obesity

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19020

Obesity

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19156

Obesity

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Oncology

Oncology

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Oncology

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR20009

Oncology

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19129

Oncology

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19023

Oncology

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Solid Tumor

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Immunology

LR19019

Atopic Dermatitis

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR20016

Atopic Dermatitis

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19055

Autoimmune Disease

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19025

Degenerative Disease

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19024

Degenerative Disease

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR21004

Osteoarthritis

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Vaccine

LR19113

Polio

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19122

6-in-1 (Diphtheriae, Tetanus, Pertussis, Hepatitis B, Meningitis, Polio)

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Dermal Filers

LR19093

Facial etc.

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR20024

Facial etc.

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR20008

Next generation filer

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Botulinum toxin

LR20023

Moderate to severe glabellar lines

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA
  • Gout is a common and complex form of inflammatory arthritis, resulting from the deposition of monosodium urate monohydrate crystals. With persistent urate crystal deposition, gout may progress from acute episodic attacks to a disabling chronic deforming arthropathy, with destructive deposits of urate crystals (tophi) in bones, joints, subcutaneous tissue, and other organs. LC350189 is a novel non-purine selective inhibitor of Xanthine Oxidase (XO). XO is needed to successively oxidize both hypoxanthine and xanthine to uric acid. Hence, this agent reduces uric acid concentrations in serum by inhibiting the production of uric acid by XO inhibition. The proposed indication of LC350189 is a treatment for chronic management of hyperuricemia in patients with gout.

    While the global gout therapeutics market is expected to reach a value of USD 8.5 billion by 2025 (CAGR: 16.1%), current therapies for chronic management of hyperuricemia in patients with gout either may not be used effectively due to titration requirement or potential safety issues. LC350189 has the potential to address the unmet clinical needs for safety and efficacy in gout treatment. LC350189 showed good systemic exposures and sUA lowering effects with no significant safety concerns in Korean and the U.S. healthy volunteers. The Phase II trial is currently on-going in the U.S.

    *LC350189 is a compound name for LR19074
  • Melanocyte-stimulating hormones, neuropeptides induced by Pro-opiomelanocortin (POMC) in the hypothalamus, act as the endogenous ligands of Melanocortin 4 receptor (MC4R). They decrease appetite by MC4R activation, leading to weight loss. Dysfunction of genes in MC4R pathway is known to cause rare genetic obesity such as POMC deficiency, leptin receptor deficiency, Bardet-Biedl syndrome and Alström syndrome. Therefore, MC4R agonists have the potential to be therapeutic agents for such genetic obesities.

    LB54640 is a first orally available, small molecule MC4R agonist. LB54640 has shown to be safe and well-tolerated in GLP toxicity studies. The efficacy and safety profiles of LB54640 observed in preclinical studies suggests that LB54640 can be a safe and effective drug for the patients with genetic obesity. The U.S. Food and Drug Administration has granted Orphan Drug Designation for LB54640 for the treatment of leptin receptor deficiency obesity. Currently, LB54640 is being evaluated in a first-in-human study in healthy, non-diabetic, obese volunteers with body mass index ≥ 27 kg/m2 in the US. This randomized, double-blind, placebo-controlled, single ascending dose and the multiple ascending dose design will assess the safety, tolerability, PK and PD of LB54640.

    *LB54640 is a compound name for LR19021
  • LG Chem 새창열림
    *CUE-101 is a compound name for LR19127

    CUE-101 is a fusion protein designed to activate and expand tumor-specific T cells, directly in the patient’s body, that target Human Papilloma 16 (HPV16)-driven malignancies. It contains IL-2 and a pMHC composed of HLA-A*02:01 complexed with a dominant peptide derived from  the E7 protein of human papilloma virus 16 (HPV 16-E7). CUE-101 is the lead immuno-oncology drug developed within the IL-2 based CUE-100 framework from Cue Biopharma’s novel Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform technology. In November 2018, LG Chem Life Sciences partnered with Cue Biopharma to develop and commercialize cancer immunotherapy drugs based on the Immuno-STAT platform technology. 

    HPV cancers account for more than 20,000 deaths each year in the US and Europe. The majority of these cancers are driven by HPV 16 which carries the E7 antigen targeted by CUE-101. Despite treatment with current standards of care, approximately 50% of patients with advanced disease will experience recurrence and significant quality of life impact. Patients with HPV-related head and neck, cervical and genitoanal cancers represent an important unmet clinical need and underscore the opportunity for promising new therapeutics.

    In preclinical studies, CUE-101 has demonstrated selective binding and preferential activation and expansion of antigen-specific T cells, dose-dependent effector cytokine production and inhibition of tumor growth both as a monotherapy and in combination with a PD-1 inhibitor.

    The Investigational New Drug (IND) application for CUE-101 was accepted by the U.S. Food and Drug Administration (FDA) in May 2019. The open-label, multi-center Phase I trial for Head and Neck Squamous Cell Carcinoma (HNSCC) patients is currently on going in the U.S.

    In addition to the CUE-101 program, CUE-102 targeting WT-1 and CUE-103 (TBD) are being developed through this partnership.

  • LG Chem 새창열림
    *PDC lung is a compound name for LR19125

    PDC* lung is an off-the shelf cancer vaccine of potent Ag-specific CD8+ T cell inducer based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC* line) originating from the French-Belgian biotech company PDC* line Pharma. PDC* lung consists of PDC* line loaded with HLA-A*02:01-restricted peptides derived from 6 antigens broadly expressed in Non-Small-Cell Lung Cancer (NSCLC). LG Chem in-licensed PDC* line’s anti-cancer vaccine in March 2019.

    PDC* lung is our leading product for NSCLC. 2.1 million new cases of lung cancer were diagnosed worldwide in 2018, and it was responsible for and 1.8 million deaths (source IARC). Lung cancer is therefore the most frequently diagnosed cancer and the leading cause of cancer mortality. About 60% of patients are diagnosed with locally advanced (stage IIIb) or metastatic (stage IV) cancer; prognosis is poor (median survival of 8-13 months).

    PDC* line is highly potent in priming and boosting fully functional antitumor CTL displaying a strong cytotoxic activity against tumor cells, and it is synergetic with the use of anti-PD-1 immune checkpoint inhibitors.  Robust results already obtained for PDC* line provide a preclinical validation, as well as ex vivo results on blood samples of lung cancer patients. An approval was granted in May, 2019 to PDC* line Pharma to launch in France and in Belgium PDC-LUNG-101 trial, an open-label, dose-escalation, Phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC* lung01, associated with or without anti-PD-1 treatment in patients with non-small-cell lung cancer.

  • LG Chem 새창열림

    LR20056 (Compound name: LG00303174) is a novel, potent, selective, and irreversible inhibitor of semicarbazide-sensitive amine oxidase (SSAO, also known as vascular adhesion protein-1 (VAP-1)) intended as an oral treatment for non-alcoholic steatohepatitis (NASH). LG Chem licensed LR20056 from TransThera Biosciences Co. Ltd. to research, develop, manufacture, and commercialize globally except China and Japan.

    NASH is a progressive form of non-alcoholic fatty liver disease (NAFLD) caused by the accumulation of excess fat in the liver. NASH is associated with chronic liver inflammation and liver cell injury, and can lead to fibrosis, cirrhosis, and liver cancer or liver failure. NAFLD and NASH are highly prevalent in patients with metabolic disorders such as type 2 diabetes and obesity. NASH is a medical disease of unmet therapeutic need with no approved treatments yet.

    LR20056 has demonstrated high selectivity over other amine oxidases (MAO-A, MAO-B, DAO) and low BBB (blood–brain barrier) penetration. So far, safety profile shows minimal potential for clinically relevant drug-drug interactions.

    The Phase 1 clinical study is currently being conducted in the U.S.

  • LG Chem 새창열림

    LR20011 (Compound name: GEN-001) is an oral microbiome therapeutic product which targets advanced solid tumors. It consists of Gram+ single strain bacteria isolated from a healthy human and identified to be the closest species of Lactococcus lactis. LG Chem licensed LR20011 from Genome & Company, a clinical stage biotechnology company based in Republic of Korea in December 2019 for development in Asia territory.

    From the preclinical studies, LR20011 has its immune response and anti-cancer effect by enhancement of dendritic cell / macrophage maturation and bacteroidales-specific memory T cell responses which leads to increase of IL-2 & IFN-γ secretion and systemic activation of CTL.

    The Phase 1/1b clinical study is currently being conducted in the U.S & KR in combination with Avelumab for PD-L1 refractory patients of solid tumors.